Suggestions
Journal Information
Vol. 30. Issue S1.
XXIV Brazilian Congress of Infectious Diseases 2025
(March 2026)
Cite
Cite
Share
Download PDF
More article options
Vol. 30. Issue S1.
XXIV Brazilian Congress of Infectious Diseases 2025
(March 2026)
507
Full text access

THIRTY-DAY SURVIVAL OF ONCOLOGIC PATIENTS WITH INFECTIONS DUE TO CARBAPENEM-RESISTANT GRAM-NEGATIVE BACTERIA: A MULTICENTER STUDY

Visits
762
Thales Baptista Guta,
Corresponding author
thales.gut@hc.fm.usp.br

Corresponding author:
, Leonardo Olimpioa, Naima Mortari e Silva Santosb, Carolina Naomi Torigoea, Valeria Cassetaric, Carolina Salume Xavierd, Cristhieni Rodriguese, Fellipe Godoyf, Eusébio Linodos Santos Juniora, Anna Sara S. Levina, Matias C. Salomãoa, Edson Abdalab, Maristela Pinheiro Freireb
a Universidade de São Paulo (USP), São Paulo, SP, Brazil
b Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, SP, Brazil
c Hospital Universitário da Universidade de São Paulo (USP), São Paulo, SP, Brazil
d Hospital Santa Rita de Cássia, Brazil
e Hospital Santa Paula, São Paulo, SP, Brazil
f Complexo Hospitalar Santa Casa de Bragança Paulista, Bragança Paulista, SP, Brazil
This item has received
Article information
Special issue
This article is part of special issue:
Vol. 30. Issue S1

XXIV Brazilian Congress of Infectious Diseases 2025

More info
Introduction/Objective

The development of antimicrobial resistance is a natural evolutionary phenomenon of bacteria and is exacerbated by intensive antibiotic use in health care, agriculture, and livestock, making infections harder to treat. This study aims to analyze factors associated with 30-day survival in oncologic patients infected with carbapenem-resistant Gram-negative bacteria (CRGNB).

Methods

Multicenter retrospective cohort study of cancer patients >17 years admitted to five centers in the states of São Paulo and Espírito Santo, Brazil, between January 2022 and December 2023, who received at least 48 hours of effective antibiotic therapy for CRGNB infections. Patients with polymicrobial infections were excluded. The outcome was death within 30 days after infection. Bi- and multivariate analyses were performed using Cox regression, and proportional hazard assumptions were assessed using Schoenfeld residual plots. Variables with p < 0.1 in bivariate analysis or with clinical/biological plausibility were included in the multivariate model. Those that reduced the −2 log-likelihood or had p ≤ 0.05 were retained in the final model.

Results

A total of 126 patients were included (mean age 60.9 ± 14.7 years); most (75.4%) had infections due to Enterobacterales, while Pseudomonas spp. (15.1%) and Acinetobacter baumannii complex (9.5%) were less frequent. The most common infectious foci were bloodstream infection (35.7%), pneumonia (25.4%), and urinary tract infections (15.1%). The 30-day survival rate was 57.1%. In multivariate analysis, factors associated with risk of death were age (HR = 1.044; p < 0.001), metastasis (HR = 2.186; p = 0.010), cirrhosis (HR = 14.677; p = 0.014), SOFA score (HR = 1.145; p < 0.001), and combination antibiotic therapy (HR = 2.216; p = 0.008). Shorter time to initiation of effective antibiotic therapy (HR = 0.803; p < 0.001) and pyelonephritis as the infectious focus (HR = 0.199; p = 0.005) were protective factors.

Conclusion

Thirty-day mortality among oncologic patients infected with CRGNB was high and influenced by factors related to infection severity, underlying disease burden, and antibiotic management. These findings reinforce the importance of rapid diagnosis and early treatment of infections in high-risk populations.

Keywords:
Cancer
Acinetobacter Baumannii
Pseudomonas Aeruginosa
Enterobacterales
Carbapenems
PDF
Full text is only available in PDF
Download PDF
The Brazilian Journal of Infectious Diseases
Article options
Tools